News

Millipore claimed that ProRes-S media offers biopharmaceutical manufacturers flexibility and increased throughput in a smaller manufacturing footprint. Millipore has developed ProRes-S media, jointly with The Dow Chemical Company.

Perseid claimed that its CTLA4-Ig product candidates (designated as MAXY-4) are designed for the treatment of a broad array of autoimmune disorders, including rheumatoid arthritis and transplant rejection.

Shire said that Daytrana, a transdermal patch that is applied to intact skin, delivers methylphenidate through the skin into the bloodstream. Daytrana showed reduction in ADHD-RS-IV total score

Apicore has partnered with a generic pharmaceutical company in 2007, to develop the API and prefilled syringes for getting approval on its ANDA to distribute a generic product

Under the collaboration Evonik and Elevance are also expected to further develop the application of metathesis catalysts within Elevance’s business scope. Elevance manufactures oils, lubricants additives, antimicrobials and

Azelastine ophthalmic solution is a prescription medication used for relieving itching caused by eye allergies. This medication comes in the form of an eye drop that is generally

AMRI is expected to screen Aquapharm’s library against Gram-negative and Gram-positive bacteria and an undisclosed anti-inflammatory target. Additionally it is also expected to isolate and elucidate the structures

Alnylam Pharma said that the study is expected to enroll approximately 28 ATTR patients. Further, the trial is designed to provide preliminary data on human proof of concept

AVI-4658 is an RNA-based therapeutic employing AVI’s new phosphorodiamidate morpholino oligomer (PMO) based chemistry and exon skipping technologies. It is being developed as a systemic treatment for patients